



Janet T. Mills
Governor

STATE OF MAINE
DEPARTMENT OF PROFESSIONAL & FINANCIAL REGULATION
OFFICE OF PROFESSIONAL AND OCCUPATIONAL REGULATION
BOARD OF PHARMACY

Penny Vaillancourt
Director



Joan F. Cohen
Commissioner

PUBLIC BOARD MEETING
July 2, 2026

AGENDA

Location:

Physical Location: Central Conference Room at the Department of Professional and Financial Regulation, Gardiner Annex, 76 Northern Avenue, Gardiner, ME

Time: 8:30 a.m.

Zoom Link: <https://mainestate.zoom.us/j/83367805178?pwd=FCsamoC688EjlJFUVUk22cF3oJeWHi.1>

Meeting ID: 833 6780 5178

Passcode: 42865626

The Zoom link for virtual observation is also posted on the board's website

www.maine.gov/pfr/professionallicensing/professions/board-pharmacy/home/board-meeting-information

Board Member Participation:

Board members may participate remotely in Board meetings pursuant to Title 1, Section 403-B and the Board Member Remote Participation Policy adopted by the Board on May 4, 2023.

Public Participation:

Regardless of whether the Board meets in-person or by remote virtual means via Zoom, the public may observe the board meeting in-person at the location described above or may choose to join virtually (see the link above).

Contact: Celia Robinson, Comprehensive Health Planner II
Phone: 207-624-8651
TTY Users Call Maine Relay 711
Email: Celia.Robinson@maine.gov

I. CALL TO ORDER

II. DRAFT MINUTES REVIEW AND APPROVAL

1. May 7, 2026
2. June 4, 2026

Office Location: 76 Northern Avenue, Gardiner, Maine 04345
Mailing Address: 35 State House Station, Augusta, Maine 04333
[Board of Pharmacy | Office of Professional and Occupational Regulation](#)

Phone: (207) 624-8651

TTY: Please Call Maine Relay 711

Fax: (207) 624-8690

III. LICENSURE APPLICATION(S)
Initial and Renewal of Individual Applications

1. Christopher Rommel Jr., PT60020794

Renewal Applications – Company (Filed beyond 10 days)

1. Dentsply Sirona Orthodontics Inc. – MF30002048
2. Digestive Care Inc. – MF30002269
3. Empower Clinic Services, LLC – MO40003120
4. Everwell Specialty Pharmacy – MO40003229
5. F & F Scottsdale – MO40003454
6. Farmakeio Outsourcing, LLC – MF30002036
7. Fresenius Kabi Compounding, LLC – MF30002059
8. G Medical, LLC – WH70001863
9. Genentech Inc. – MF30002177
10. Get Relief Rx LLC – MO40003559
11. Goot Nursing Home Pharmacy Inc. – MO40002296
12. Hepalink USA Inc. – MF30002138
13. Homemed Pharmacy, LLC – MO40003346
14. Medminder Systems Inc. – MO40003379
15. Musely Compounding Pharmacy East LLC – MO40003414
16. New England Life Care – MO40001347
17. Neogen Corporation – WH70003492
18. New England Life Care – MO40002381
19. North American Custom Laboratories – MO40002026
20. Nufactor Inc. – MO40003335
21. Nutrishare, LLC – MO40003011
22. One Way Drug, LLC – MO40002289
23. Optum Pharmacy 704 Inc. – MO40002639
24. Oryza Pharmaceuticals Inc. – MF30002113
25. Padagis South Carolina, LLC – WH70003405
26. Pharmacy Associates Inc. – MO40002651
27. Prasco, LLC – WH70001411
28. Prasco. LLC – WH70002871
29. Precision Medication Inc. – MO40003539
30. Procure LTC of MA, LLC – MO40003267
31. Propharma Distribution, LLC – WH70002781
32. Prosperity Pharmacy Med Center Inc. – MO40003310
33. Quality Compounding Rx of America – MO40003574
34. Realo Specialty Pharmacy Inc. – MO40003679
35. Revive Rx. LLC – MO40003402
36. RPC2B, LLC – MO40003277
37. Right Value Drug Stores, LLC – MO40002780
38. Smith & Nephew Inc. – WH70001999
39. Stokes Healthcare Inc. – MF30001717
40. Tailstorm Health Inc. – MF30001842
41. Tomeldon Co. Inc. – MO40003013



LICENSURE APPLICATION(S) (cont.)

- 42. Village Lane Apothecary – MO40003236
- 43. Walgreens.com Inc. – MO40002178
- 44. Westchester Compounding Pharmacy Inc.- MO40003185
- 45. West 35th Apothecary, LLC – MO40003514
- 46. Xttrium Laboratories Inc. – MF30002293

IV. COMPLAINT CASES – Initial Presentations

- 1. 2026-PHA-21209
- 2. 2026-PHA-21302
- 3. 2026-PHA-21303
- 4. 2026-PHA-21333
- 5. 2026-PHA-21357

V. RULEMAKING ACTIVITY

- 1. Proposed Rulemaking Review: Chapter 1, Definitions, Chapter 20-A, Self-Service Customer Kiosks, Chapter 21, Centralized Pharmacy Services, and Chapter 24, Retention of Records by Pharmacies, Including Action on Comments Received During 30-day Comment Period

VI. NATIONAL ASSOCIATION OF BOARDS OF PHARMACY (NABP)

- 1. Report on Annual Meeting – May 12-15, 2026

VII. CORRESPONDENCE

- 1. April 26, 2026 emails from the Maine Board of Licensure in Medicine (confidential)
- 2. April 30, 2026, emails from National Association of Boards of Pharmacy (NABP)
- 3. May 1, 2026, emails from National Association of Boards of Pharmacy (NABP)
- 4. May 7, 2026, emails from National Association of Boards of Pharmacy (NABP)
- 5. June 2, 2026 email from Kyla Perrotta re: manufacturing licensure requirements
- 6. June 11, 2026, emails from National Association of Boards of Pharmacy (NABP)
- 7. June 18, 2026, emails from National Association of Boards of Pharmacy (NABP)

VIII. OPOP DIRECTOR REPORT

IX. PUBLIC OPPORTUNITY TO COMMENT

(Board President Statement) “Under this item, the Board may offer an opportunity to members of the public listening in to comment on any public matter under the jurisdiction of the Board. While the Board cannot take action on any issues presented, nor can it respond to or debate decisions made today, including matters relating to complaint cases that may be on the agenda. The board will listen to comments and may ask staff to place the issue on a subsequent agenda. At the discretion of the Board President a time limit on comments may be set.”



X. ADJOURNMENT

Pursuant to 1 M.R.S. §406 public notice has been met by publication in an area newspaper where the meeting is held. This is a virtual board meeting and is open to members of the public, but not for public participation. Information to join this meeting is on the Board's website. Please contact Celia Robinson if you wish to confirm this meeting date or check our web site at www.maine.gov/professionallicensing. The Board may address agenda items out of sequence to accommodate persons appearing before the Board or to aid in the efficiency or effectiveness of the meeting. The Board may combine two or more agenda items for consideration. The Board may remove an item from the agenda or delay discussion relating to an item on the agenda.

